BCKDHA
Basic information
Region (hg38): 19:41397808-41425002
Previous symbols: [ "OVD1A" ]
Links
Phenotypes
GenCC
Source:
- maple syrup urine disease type 1A (Definitive), mode of inheritance: AR
- maple syrup urine disease (Definitive), mode of inheritance: AR
- maple syrup urine disease (Definitive), mode of inheritance: AR
- maple syrup urine disease (Strong), mode of inheritance: AR
- classic maple syrup urine disease (Supportive), mode of inheritance: AR
- intermediate maple syrup urine disease (Supportive), mode of inheritance: AR
- intermittent maple syrup urine disease (Supportive), mode of inheritance: AR
- thiamine-responsive maple syrup urine disease (Supportive), mode of inheritance: AR
- maple syrup urine disease type 1A (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Maple syrup urine disease, type Ia | AR | Biochemical | Dietary measures (eg, leucine restriction, high-calorie branched chain amino acid-free formulas, isoleucine and valine supplementation) combined with careful surveillance can be beneficial to prevent decompensation and minimize disease sequelae; specific treatment in times of metabolic decompensation can reduce morbidity and mortaility; Liver transplantation is effective for classic MSUD; Specific monitoring is indicated in pregnancy | Biochemical; Neurologic | 8037208; 7883996; 7672509; 11112664; 12042535; 14567968; 14742428; 17922217; 18378174; 20301313; 20301495; 20061171; 22326532 |
ClinVar
This is a list of variants' phenotypes submitted to
- Maple syrup urine disease (51 variants)
- not provided (16 variants)
- Maple syrup urine disease type 1A (11 variants)
- Inborn genetic diseases (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the BCKDHA gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 193 | 200 | ||||
missense | 37 | 101 | 155 | |||
nonsense | 19 | 22 | 41 | |||
start loss | 1 | |||||
frameshift | 24 | 28 | 53 | |||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 17 | 22 | ||||
splice region | 1 | 3 | 36 | 4 | 44 | |
non coding | 17 | 113 | 17 | 148 | ||
Total | 55 | 107 | 125 | 315 | 23 |
Highest pathogenic variant AF is 0.0000792
Variants in BCKDHA
This is a list of pathogenic ClinVar variants found in the BCKDHA region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-41397824-C-CAAGATGGCGGTAGCGGACGGGCGAGGTGGCTCACGCCTGAAATCCCAGCACTATGGGAGGCCGAGGCGGGCGGATCACGAGGTCAGGANNNNNNNNNNAAAAAAAAAAAAAAAAAAAA | Maple syrup urine disease | Pathogenic (May 18, 2022) | ||
19-41397830-G-A | Maple syrup urine disease | Likely pathogenic (Jan 15, 2018) | ||
19-41397833-G-A | Maple syrup urine disease | Likely benign (Nov 20, 2021) | ||
19-41397839-G-A | Maple syrup urine disease | Likely benign (Apr 11, 2023) | ||
19-41397839-G-C | Maple syrup urine disease | Likely benign (Oct 03, 2021) | ||
19-41397840-AT-A | Maple syrup urine disease | Pathogenic/Likely pathogenic (Jan 31, 2024) | ||
19-41397841-T-C | Inborn genetic diseases | Uncertain significance (May 10, 2023) | ||
19-41397842-C-A | Maple syrup urine disease | Likely benign (Jan 28, 2024) | ||
19-41397842-C-T | not specified • Maple syrup urine disease • Maple syrup urine disease type 1A • Inborn genetic diseases | Benign/Likely benign (Jan 28, 2024) | ||
19-41397848-A-C | Inborn genetic diseases • Maple syrup urine disease | Likely benign (Jan 25, 2024) | ||
19-41397848-A-G | Inborn genetic diseases • Maple syrup urine disease | Likely benign (Aug 14, 2023) | ||
19-41397849-G-C | Inborn genetic diseases | Uncertain significance (Nov 02, 2021) | ||
19-41397851-G-A | Maple syrup urine disease | Likely benign (Mar 11, 2019) | ||
19-41397854-G-A | Maple syrup urine disease | Likely benign (Oct 31, 2022) | ||
19-41397855-G-T | Maple syrup urine disease | Uncertain significance (Aug 27, 2021) | ||
19-41397857-C-G | Maple syrup urine disease | Likely benign (Nov 04, 2020) | ||
19-41397857-C-T | Maple syrup urine disease | Likely benign (Apr 24, 2023) | ||
19-41397859-G-A | Maple syrup urine disease | Likely pathogenic (Oct 28, 2023) | ||
19-41397860-G-A | Maple syrup urine disease | Pathogenic (Jun 25, 2021) | ||
19-41397861-C-A | not specified • Maple syrup urine disease • Maple syrup urine disease type 1A | Benign/Likely benign (Feb 01, 2024) | ||
19-41397862-G-A | Maple syrup urine disease | Uncertain significance (Jul 06, 2022) | ||
19-41397862-G-C | Maple syrup urine disease • Inborn genetic diseases | Conflicting classifications of pathogenicity (Mar 06, 2024) | ||
19-41397865-TA-T | Maple syrup urine disease | Pathogenic (Aug 09, 2022) | ||
19-41397866-A-G | Maple syrup urine disease | Likely benign (Feb 05, 2023) | ||
19-41397869-C-T | Maple syrup urine disease | Likely benign (Dec 18, 2020) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
BCKDHA | protein_coding | protein_coding | ENST00000269980 | 9 | 46696 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
9.82e-9 | 0.758 | 125702 | 0 | 46 | 125748 | 0.000183 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.684 | 256 | 289 | 0.887 | 0.0000198 | 2908 |
Missense in Polyphen | 80 | 110.09 | 0.72668 | 1050 | ||
Synonymous | 0.0715 | 120 | 121 | 0.992 | 0.00000903 | 870 |
Loss of Function | 1.44 | 16 | 23.5 | 0.680 | 0.00000131 | 238 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000388 | 0.000388 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000544 | 0.0000544 |
Finnish | 0.0000929 | 0.0000924 |
European (Non-Finnish) | 0.000177 | 0.000176 |
Middle Eastern | 0.0000544 | 0.0000544 |
South Asian | 0.000371 | 0.000359 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: The branched-chain alpha-keto dehydrogenase complex catalyzes the overall conversion of alpha-keto acids to acyl-CoA and CO(2). It contains multiple copies of three enzymatic components: branched-chain alpha-keto acid decarboxylase (E1), lipoamide acyltransferase (E2) and lipoamide dehydrogenase (E3).;
- Disease
- DISEASE: Maple syrup urine disease 1A (MSUD1A) [MIM:248600]: A metabolic disorder due to an enzyme defect in the catabolic pathway of the branched-chain amino acids leucine, isoleucine, and valine. Accumulation of these 3 amino acids and their corresponding keto acids leads to encephalopathy and progressive neurodegeneration. Clinical features include mental and physical retardation, feeding problems, and a maple syrup odor to the urine. The keto acids of the branched-chain amino acids are present in the urine. If untreated, maple syrup urine disease can lead to seizures, coma, and death. The disease is often classified by its pattern of signs and symptoms. The most common and severe form of the disease is the classic type, which becomes apparent soon after birth. Variant forms of the disorder become apparent later in infancy or childhood and are typically milder, but they still involve developmental delay and other medical problems if not treated. {ECO:0000269|PubMed:1867199, ECO:0000269|PubMed:1885764, ECO:0000269|PubMed:2060625, ECO:0000269|PubMed:21844576, ECO:0000269|PubMed:2241958, ECO:0000269|PubMed:2703538, ECO:0000269|PubMed:7883996, ECO:0000269|PubMed:8037208, ECO:0000269|PubMed:8161368}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Propanoate metabolism - Homo sapiens (human);Valine, leucine and isoleucine degradation - Homo sapiens (human);3-Methylglutaconic Aciduria Type I;Valine, Leucine and Isoleucine Degradation;2-Methyl-3-Hydroxybutryl CoA Dehydrogenase Deficiency;Isovaleric Aciduria;3-Methylcrotonyl Coa Carboxylase Deficiency Type I;Propionic Acidemia;Maple Syrup Urine Disease;3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency;Isobutyryl-coa dehydrogenase deficiency;3-hydroxyisobutyric aciduria;3-hydroxyisobutyric acid dehydrogenase deficiency;Isovaleric acidemia;Methylmalonate Semialdehyde Dehydrogenase Deficiency;Methylmalonic Aciduria;3-Methylglutaconic Aciduria Type IV;3-Methylglutaconic Aciduria Type III;Threonine and 2-Oxobutanoate Degradation;Beta-Ketothiolase Deficiency;Lipid Metabolism Pathway;Branched-chain amino acid catabolism;Metabolism of amino acids and derivatives;leucine degradation;Metabolism;valine degradation;threonine degradation;Valine, leucine and isoleucine degradation;isoleucine degradation;Glyoxylate metabolism and glycine degradation;2-oxoisovalerate decarboxylation to isobutanoyl-CoA;2-oxobutanoate degradation;superpathway of methionine degradation
(Consensus)
Recessive Scores
- pRec
- 0.109
Intolerance Scores
- loftool
- 0.204
- rvis_EVS
- -1.02
- rvis_percentile_EVS
- 8.04
Haploinsufficiency Scores
- pHI
- hipred
- N
- hipred_score
- 0.165
- ghis
- 0.498
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.972
Mouse Genome Informatics
- Gene name
- Bckdha
- Phenotype
Gene ontology
- Biological process
- branched-chain amino acid catabolic process;oxidation-reduction process
- Cellular component
- mitochondrion;mitochondrial matrix;mitochondrial alpha-ketoglutarate dehydrogenase complex
- Molecular function
- alpha-ketoacid dehydrogenase activity;3-methyl-2-oxobutanoate dehydrogenase (2-methylpropanoyl-transferring) activity;protein binding;carboxy-lyase activity;metal ion binding